In our study, all patients harbored additional mutations, TET1/2 (52/91, 57.1%) was the most common co‐mutation, followed by IDH1/2 (36/91, 39.6%), DNMT3A (35/91, 38.5%), MDS‐related genes (ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 genes) (35/91, 38.5%), FLT3‐TKD (27/91, 29.7%), and GATA2 (13/91, 14.3%) mutations (Table 1). The gene discussed is SRSF2; the disease is myelodysplastic syndrome.